MohammadAlsharabatiMD
Neurology • Des Moines, IANeuromuscular Medicine, Neurophysiology
Clinical Assistant Professor, Neurology, University of Iowa
Dr. Alsharabati is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1221 Pleasant Street
Suite 300
Des Moines, IA 50309Phone+1 515-241-4200Fax+1 515-241-4083
Education & Training
University of Alabama Medical CenterFellowship, Clinical Neurophysiology, 2008 - 2009
University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Neurology, 2005 - 2008
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalInternship, Internal Medicine, 2004 - 2005
University of Jordan Faculty of MedicineClass of 2003
Certifications & Licensure
IA State Medical License 2016 - 2025
AL State Medical License 2008 - 2024
OH State Medical License 2009 - 2011- American Board of Psychiatry and Neurology Neurology
- American Board of Psychiatry and Neurology Neuromuscular Medicine
Clinical Trials
- A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) Start of enrollment: 2011 Jun 01
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Start of enrollment: 2012 Mar 01
- Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) Start of enrollment: 2013 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 9 citationsFilamentous tangles with nemaline rods in MYH2 myopathy: a novel phenotypeNicolas N. Madigan, Michael J. Polzin, Gaofeng Cui, Teerin Liewluck, Mohammad H. Alsharabati
Acta Neuropathologica Communications. 2021-04-29 - 391 citationsSafety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-bli...James F. Howard, Kimiaki Utsugisawa, Michael Benatar, Hiroyuki Murai, Richard J. Barohn
The Lancet. Neurology. 2017-12-01 - 33 citationsAmifampridine phosphate (Firdapse(®)) is effective and safe in a phase 3 clinical trial in LEMS.Shin J. Oh, Natalya Shcherbakova, Anna Kostera-Pruszczyk, Mohammad Alsharabati, Mazen M. Dimachkie
Muscle & Nerve. 2016-05-01
Press Mentions
Strange Signs: Cancer-Related Paraneoplastic SyndromesNovember 15th, 2019
Professional Memberships
- Member
Other Languages
- Arabic
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
